News

ctDNA to Guide Panitumumab Rechallenge in Metastatic Colorectal Cancer

News /

Monoclonal antibodies against epidermal growth factor receptor (EGFR) are approved for the treatment of metastatic RAS-like colorectal cancer (WT), but the emergence of resistance mutations restricts their efficacy. Previous studies demonstrated that mutant alleles of RAS, BRAF and EGFR, which appear in circulating tumor DNA (ctDNA) during blockade, decrease upon withdrawal of therapy. CHRONOS hypothesized that […]

ctDNA to Guide Panitumumab Rechallenge in Metastatic Colorectal Cancer Read More »

TABRECTA GAINS FULL FDA APPROVAL FOR NON-SMALL CELL LUNG CANCER

News /

The U.S. Food and Drug Administration (FDA) has approved the drug capmatinib (Tabrecta) for adult patients with metastatic non-small cell lung cancer (NSCLC), whose tumors have a genetic mutation that results in the loss of exon 14 of the MET (mesenchymal-epithelial transition gene) gene. The approval was based on a trial of 160 patients with

TABRECTA GAINS FULL FDA APPROVAL FOR NON-SMALL CELL LUNG CANCER Read More »

PEMBROLIZUMAB PLUS CHEMOTHERAPY IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER

News /

Javier Cortes and his research team have conducted a clinical trial, currently in phase 3, to study the effect of adding pembrolizumab to standard chemotherapy in patients with advanced triple-negative breast cancer whose tumors expressed programmed death ligand 1 (PD-L1) with a combined positive score (CPS) of 10 or more. The results show that the

PEMBROLIZUMAB PLUS CHEMOTHERAPY IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER Read More »

DIAGNOSIS AND MANAGEMENT OF AML IN ADULTS: 2022 ELN RECOMMENDATIONS FROM AN INTERNATIONAL EXPERT PANEL

News /

The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease

DIAGNOSIS AND MANAGEMENT OF AML IN ADULTS: 2022 ELN RECOMMENDATIONS FROM AN INTERNATIONAL EXPERT PANEL Read More »

ADAGRASIB FOR PATIENTS WITH ADVANCED LUNG CANCER WITH KRAS G12C MUTATION

News /

Adagrasib is a KRAS G12C mutation inhibitor that has been studied for the past several years in patients with these mutations. This drug is similar to Sotorasib, which is FDA approved and available for use. Adagrasib appears to have good efficacy in a subset of patients with non-small cell lung cancer with the G12C mutation

ADAGRASIB FOR PATIENTS WITH ADVANCED LUNG CANCER WITH KRAS G12C MUTATION Read More »

IMMUNOTHERAPY SHOWS 100% RESPONSE RATE IN CERTAIN RECTAL CANCER PATIENTS

News /

Rectal cancer, a rare neoplasm related to colon cancer, is usually diagnosed at an advanced stage, when it is more difficult to treat. The standard treatment for locally advanced rectal cancer is neoadjuvant (preoperative) chemotherapy and radiation therapy to shrink tumors, followed by surgery to remove all or part of the rectum, which may require

IMMUNOTHERAPY SHOWS 100% RESPONSE RATE IN CERTAIN RECTAL CANCER PATIENTS Read More »

IBSAL SCIENTISTS PREDICT PROGNOSIS LUNG CANCER PATIENTS BY STUDYING A SPECIFIC GENE

News /

Researchers from the Molecular Pathology research group at the Institute of Biomedical Research of Salamanca (IBSAL), led by Mª Dolores Ludeña, professor at the University of Salamanca (USAL) and belonging to the Pathological Anatomy Service of the University Clinical Hospital of Salamanca, have identified new genetic alterations in squamous lung cancer, the most common subtype

IBSAL SCIENTISTS PREDICT PROGNOSIS LUNG CANCER PATIENTS BY STUDYING A SPECIFIC GENE Read More »

FDA APPROVES TRASTUZUMAB DERUXTECAN FAM-TRASTUZUMAB DERUXTECAN-NXKI FOR BREAST CANCER

News /

On May 4, 2022, the Food and Drug Administration (FDA) approved Enhertu (trastuzumab deruxtecan) treatment from Daiichi Sankyo Company and AstraZeneca, for adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received two or more treatment regimens based on anti-HER2 therapies. The treatment is approved in the metastatic setting or in the

FDA APPROVES TRASTUZUMAB DERUXTECAN FAM-TRASTUZUMAB DERUXTECAN-NXKI FOR BREAST CANCER Read More »

NEW DRUG CANDIDATE TO BLOCK TUMOR STEM CELLS TUMOR STEM CELLS

News /

An international consortium led by IRB Barcelona and the company Merus has discovered MCLA-158, an antibody that targets cancer stem cells in solid tumors and prevents metastasis in experimental models. The MCLA-158 antibody, commercially known as Petosemtamab, is a bispecific antibody that recognizes two distinct proteins on the surface of cancer stem cells, namely EGFR

NEW DRUG CANDIDATE TO BLOCK TUMOR STEM CELLS TUMOR STEM CELLS Read More »

FDA APPROVES ALPELISIB FOR PIK3CA-RELATED OVERGROWTH SPECTRUM

News /

On April 5, 2022, the Food and Drug Administration (FDA) approved alpelisib (Vijoice, Novartis Pharmaceuticals) treatment for adult and pediatric patients aged two years and older with severe manifestations of the spectrum of PIK3CA-related overgrowth syndromes (PROS) requiring systemic treatment. Efficacy was evaluated using a clinical trial of 37 patients over two years of age

FDA APPROVES ALPELISIB FOR PIK3CA-RELATED OVERGROWTH SPECTRUM Read More »

Descargar más información